

The role of substance P in the
progression and complications of
secondary brain tumours

Kate Lewis, BHlthSc (Hons)

*Discipline of Anatomy and Pathology, School of Medical Sciences
The University of Adelaide*

August 2012

Thesis submitted to The University of Adelaide in partial fulfilment of the
requirements for the degree of Doctor of Philosophy

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Kate Lewis and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Kate Lewis

Date:

Publications

The following articles have been published or accepted for publication during the period of my PhD candidature, and sections of these articles are included in the present thesis.

Lewis KM, Harford-Wright E, Vink R, Ghabriel MN. (2012) Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. *Journal of Neuroimmunology*; 250: 59-65.

Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN. (2012) Walker 256 tumour cells increase Substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. *Clinical and Experimental Metastases*. Paper accepted on 8th May 2012, DOI: 10.1007/s10585-012-9487-z

Harford-Wright E, Lewis KM, Vink R. (2011) Towards drug discovery for brain tumours: interaction of kinins and tumours at the blood brain barrier interface. *Recent Patents in CNS Drug Discovery*; 6: 31-40.

Submitted manuscripts:

Lewis KM, Harford-Wright E, Vink R, Ghabriel MN. NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. *Anti-Cancer Drugs*.

Lewis KM, Harford-Wright E, Vink R, Ghabriel MN. Tumorigenicity of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours. *Cancer Cell International*.

Acknowledgements

This PhD project was made possible by the support and expertise of many people who I express my gratitude to here.

In particular, I would like to thank my supervisors for their valuable guidance, Associate Professor Mounir Ghabriel and Professor Robert Vink.

I would also like to acknowledge the assistance, advice and support of my colleagues within the laboratory, past and present. This includes but is not limited to Elizabeth Harford-Wright, Christine Barry, Anna Leonard, Frances Corrigan, Emma Thornton, Renee Turner, Jenna Ziebell, Stephen Helps, Corrina Van Den Heuvel, Adam Wells, Levon Gabrielian, Tim Kleinig and Naiomi Cook.

Valued technical assistance was provided by Jim Manivas and the helpful staff in the Neurological Diseases Laboratory in the IMVS. Animal care and support were provided by Brian Lewis and the animal house staff of the IMVS.

This project was generously supported by the Neurosurgical Research Foundation.

Special thanks to my friends and family for all of their loving support and especially my parents for their tolerance and enthusiasm.

Abbreviations

°C	Degrees Celsius
μL	Micro Litres
μm	Micro Metres
AQP-4	Aquaporin-4
AQP-1	Aquaporin-1
BBB	Blood-Brain Barrier
CCA	Common Carotid Artery
CNS	Central Nervous System
CPP	Cerebral Perfusion Pressure
CSF	Cerebrospinal Fluid
d	Days
DAB	3,3'-diaminobenzidine
Dex	Dexamethasone
ECA	External Carotid Artery
GFAP	Glial Fibrillary Acidic Protein
H & E	Haematoxylin and Eosin
h	Hours
IBA1	Ionized Calcium Binding Adaptor Molecule 1
ICA	Internal Carotid Artery
ICP	Intra-cranial Pressure

IFN- γ	Interferon Gamma
IL-6	Interleukin-6
IL-11	Interleukin-11
iNOS	Inducible Nitric Oxide Synthase
IU	International Units
MAP	Mean Arterial Pressure
mg	Milligrams
mL	Millilitres
mm	Millimetres
MRI	Magnetic Resonance Imaging
n	Number
NAT	n-acetyl L-tryptophan
NHS	Normal Horse Serum
OA	Ophthalmic Artery
PPT-A	Pre Protachykinin-A
RPM	Revolutions per Minute
SEM	Standard Error of the Mean
SP	Substance P
STA	Superior Thyroid Artery
TJ	Tight Junction
TNF- α	Tumour Necrosis Factor Alpha

VEGF Vascular Endothelial Growth Factor

wk Weeks

Table of Contents

DECLARATION	II
PUBLICATIONS	III
ACKNOWLEDGEMENTS	V
ABBREVIATIONS	VI
TABLE OF CONTENTS	IX
LIST OF TABLES AND FIGURES:	XIII
ABSTRACT	XV
1 INTRODUCTION	1
1.1 EPIDEMIOLOGY OF BRAIN METASTASES	1
1.1.1 <i>Incidence</i>	1
1.1.2 <i>Organ of origin</i>	2
1.2 LOCATION OF METASTATIC TUMOUR	3
1.3 CLINICAL RELEVANCE	3
1.4 TUMOUR ASSOCIATED MORBIDITY	4
1.4.1 <i>Seizures</i>	4
1.5 CURRENT TREATMENTS FOR METASTATIC BRAIN TUMOURS	5
1.5.1 <i>Chemotherapy</i>	5
1.5.2 <i>Radiation therapy</i>	7
1.5.3 <i>Dexamethasone</i>	7
1.6 BLOOD BRAIN BARRIER	10
1.6.1 <i>Cerebral capillary endothelial cells</i>	10
1.6.2 <i>Tight junctions</i>	10
1.6.3 <i>Basement membrane</i>	11
1.6.4 <i>Astrocytes</i>	11
1.6.5 <i>Pericytes</i>	11
1.7 FORMATION OF BRAIN METASTASES	12
1.7.1 <i>Immune system interactions</i>	14
1.8 EXPERIMENTAL MODELS OF BRAIN METASTASES.....	16
1.8.1 <i>Tumour injection into the internal carotid artery</i>	16
1.8.2 <i>Syngeneic model</i>	17
1.8.3 <i>Walker 256 breast carcinoma</i>	17
1.9 FEATURES OF METASTATIC BRAIN TUMOURS	19
1.9.1 <i>Tumour morphology</i>	19
1.9.2 <i>Tumour border</i>	19
1.9.3 <i>Blood-tumour barrier</i>	19
1.9.4 <i>Angiogenesis</i>	21
1.9.5 <i>Peri-tumoral environment</i>	22
1.10 PERITUMORAL OEDEMA.....	22
1.10.1 <i>Tumour size</i>	23
1.10.2 <i>Complications of cerebral oedema</i>	23
1.10.3 <i>Clearance of oedema</i>	24
1.11 SUBSTANCE P	24
1.11.1 <i>Immunoreactivity in the brain</i>	25
1.11.2 <i>Substance P effects on the blood-brain barrier</i>	26

1.11.3	<i>Substance P and oedema formation</i>	26
1.11.4	<i>Substance P and NK1 expression in cancer cells</i>	28
1.11.5	<i>Role of substance P and NK1 receptors on cancer growth</i>	33
1.11.6	<i>Substance P effects on angiogenesis</i>	40
1.11.7	<i>Substance P interactions with radiotherapy of cancer</i>	40
1.11.8	<i>Potential effects of Substance P on tumour cell extravasation into the brain</i> 41	
1.12	CONCLUSION	41
2	MATERIALS AND METHODS	42
2.1	CELL CULTURE	42
2.1.1	<i>Walker 256 cells from American Type Culture Collection</i>	42
2.1.2	<i>Walker 256 cells from Cell Resource Centre at Tohoku University</i>	42
2.1.3	<i>Cell viability assay</i>	43
2.2	ANIMALS	43
2.3	INTERNAL CAROTID ARTERY INJECTION.....	44
2.4	DIRECT INTRACEREBRAL INOCULATION	47
2.5	DRUG TREATMENTS.....	47
2.5.1	<i>Emend</i>	47
2.5.2	<i>NAT</i>	48
2.5.3	<i>Dexamethasone</i>	48
2.6	ASSESSMENT OF BRAIN HISTOLOGY	48
2.7	TUMOUR VOLUME	49
2.8	IMMUNOHISTOCHEMISTRY	49
2.9	BRAIN WATER CONTENT	50
2.10	EVANS BLUE EXTRAVASATION	50
2.11	STATISTICAL ANALYSIS	51
3	TUMORIGENICITY OF WALKER 256 BREAST CARCINOMA CELLS FROM TWO DIFFERENT TUMOUR CELL BANKS AS ASSESSED USING TWO MODELS OF BRAIN METASTASES	52
3.1	ABSTRACT	52
3.2	INTRODUCTION.....	53
3.3	METHOD.....	54
3.3.1	<i>Cell Culture</i>	54
3.3.2	<i>Animals</i>	54
3.3.3	<i>Internal Carotid Artery Injection</i>	54
3.3.4	<i>Direct Inoculation</i>	55
3.3.5	<i>Tumour Volume</i>	55
3.3.6	<i>Immunohistochemistry</i>	55
3.3.7	<i>Statistical Analysis</i>	56
3.4	RESULTS.....	57
3.4.1	<i>Cell Morphology</i>	57
3.4.2	<i>Tumorigenicity</i>	58
3.4.3	<i>Tumour Interactions with the BBB</i>	63
3.4.4	<i>Brain Microenvironment</i>	65
3.5	DISCUSSION.....	69
4	WALKER 256 TUMOUR CELLS INCREASE SUBSTANCE P IMMUNOREACTIVITY LOCALLY AND MODIFY THE PROPERTIES OF	

THE BLOOD-BRAIN BARRIER DURING EXTRAVASATION AND BRAIN INVASION	74
4.1 ABSTRACT	74
4.2 INTRODUCTION	75
4.3 METHODS	78
4.3.1 <i>Animals</i>	78
4.3.2 <i>Cell Culture</i>	78
4.3.3 <i>Internal Carotid Artery Inoculation</i>	78
4.3.4 <i>Tumour Volume</i>	78
4.3.5 <i>Immunolabelling</i>	79
4.3.6 <i>Immunolabelling analysis</i>	79
4.4 RESULTS	80
4.5 DISCUSSION	89
5 NK1 ANTAGONIST TREATMENT IS NOT SUFFICIENT TO PREVENT WALKER 256 BREAST CARCINOMA EXTRAVASATION AND METASTATIC BRAIN TUMOUR DEVELOPMENT.....	94
5.1 ABSTRACT	94
5.2 INTRODUCTION	95
5.3 METHOD	97
5.3.1 <i>Animals</i>	97
5.3.2 <i>Cell culture</i>	97
5.3.3 <i>Internal carotid artery inoculation</i>	97
5.3.4 <i>Treatment</i>	97
5.3.5 <i>Immunostaining</i>	98
5.3.6 <i>Tumour volume</i>	98
5.3.7 <i>Statistical analysis</i>	98
5.4 RESULTS	99
5.5 DISCUSSION	103
6 TARGETING CLASSICAL BUT NOT NEUROGENIC INFLAMMATION REDUCES PERITUMORAL OEDEMA IN SECONDARY BRAIN TUMOURS 106	
6.1 ABSTRACT	106
6.2 INTRODUCTION	107
6.3 METHODS	110
6.3.1 <i>Animals</i>	110
6.3.2 <i>Cell culture</i>	110
6.3.3 <i>Tumour inoculation</i>	110
6.3.4 <i>Treatment</i>	110
6.3.5 <i>Immunostaining</i>	111
6.3.6 <i>Brain Water Content</i>	111
6.3.7 <i>Evans blue extravasation</i>	111
6.3.8 <i>Statistical Analysis</i>	112
6.4 RESULTS	113
6.4.1 <i>SP immunoreactivity</i>	113
6.4.2 <i>Brain water content</i>	115
6.4.3 <i>Blood-brain barrier permeability</i>	115
6.5 DISCUSSION	120

7	NK1 RECEPTOR ANTAGONISTS AND DEXAMETHASONE AS ANTICANCER AGENTS IN VITRO AND IN A MODEL OF BRAIN TUMOURS SECONDARY TO BREAST CANCER.....	124
7.1	ABSTRACT.....	124
7.2	INTRODUCTION.....	125
7.3	MATERIALS AND METHODS.....	128
7.3.1	<i>Cell Viability Assay</i>	128
7.3.2	<i>Cell Culture for Inoculation</i>	128
7.3.3	<i>Animals</i>	128
7.3.4	<i>Tumour Inoculation</i>	128
7.3.5	<i>Treatment</i>	128
7.3.6	<i>Tumour Volume</i>	129
7.3.7	<i>Immunostaining</i>	129
7.3.8	<i>Analysis of NK1 receptor, GFAP and IBA1 immunostained sections</i> ...	129
7.3.9	<i>Tumour cell replication, density and apoptosis</i>	130
7.3.10	<i>Statistical Analysis</i>	130
7.4	RESULTS.....	131
7.4.1	<i>Cell Viability Assay</i>	131
7.4.2	<i>NK1 receptor expression</i>	133
7.4.3	<i>Tumour Growth</i>	134
7.4.4	<i>Brain microenvironment</i>	138
7.5	DISCUSSION.....	143
8	GENERAL DISCUSSION.....	149
8.1	PURPOSE.....	149
8.2	MODELS USED.....	150
8.3	PRINCIPAL FINDINGS.....	151
8.4	FURTHER RESEARCH.....	159
8.5	CONCLUSION.....	161
9	REFERENCE LIST	162

LIST OF TABLES AND FIGURES:

TABLE 1.1	EXPRESSSION OF SUBSTANCE P (SP) AND NK1 RECEPTORS IN HUMAN CANCER SPECIMENS	29
TABLE 1.2	EXPRESSION OF SUBSTANCE P (SP) AND NK1 RECEPTORS IN CANCER CELL LINES	31
TABLE 1.3	EFFECT OF EXOGENOUS SUBSTANCE P (SP) APPLICATION AND NK1 ANTAGONIST TREATMENT ON CANCER CELLS IN VITRO	36
TABLE 1.4	SUBSTANCE P (SP) AND NK1 ANTAGONIST EFFECTS ON CANCER IN VIVO	39
FIGURE 2.1	INTERNAL CAROTID ARTERY INJECTION.....	46
FIGURE 3.1	TUMOUR CELL MORPHOLOGY IN VITRO AND IN VIVO	58
TABLE 3.1	TUMOUR INCIDENCE IN ANIMALS INJECTED VIA THE INTERNAL CAROTID ARTERY OR DIRECTLY INOCULATED INTO THE BRAIN WITH WALKER 256 BREAST TUMOUR CELLS OBTAINED FROM THE CELL RESOURCE CENTRE FOR MEDICAL RESEARCH AT TOHOKU UNIVERSITY (CRCTU) OR THE AMERICAN TYPE CULTURE COLLECTION (ATCC).....	60
FIGURE 3.2	TUMOUR VOLUME IN MODELS OF BRAIN METASTASES	61
FIGURE 3.3	EXTRACRANIAL TUMOUR GROWTH FOLLOWING INTERNAL CAROTID ARTERY INJECTION OF CRCTU WALKER 256 CELLS.....	62
FIGURE 3.4	ALBUMIN IMMUNOREACTIVITY IN METASTATIC BRAIN TUMOUR MODELS	64
FIGURE 3.5	GFAP IMMUNOREACTIVITY IN METASTATIC BRAIN TUMOUR MODELS	66
FIGURE 3.6	IBA1 IMMUNOREACTIVITY IN METASTATIC BRAIN TUMOUR MODELS	68
TABLE 4.1	TUMOUR INCIDENCE OVER TIME.....	80
FIGURE 4.1	TUMOUR GROWTH OVER TIME.....	81
FIGURE 4.2	ALBUMIN IMMUNOREACTIVITY OVER TIME.....	83
FIGURE 4.3	ENDOTHELIAL BARRIER ANTIGEN (EBA) IMMUNOREACTIVITY	85
FIGURE 4.4	SUBSTANCE P (SP) IMMUNOREACTIVITY WITH TUMOUR INVASION	87
FIGURE 4.5	SUBSTANCE P (SP) IMMUNOREACTIVITY SURROUNDING ESTABLISHED BRAIN METASTASES.....	88
TABLE 5.1	EFFECT OF TREATMENT ON INCIDENCE OF METASTATIC BRAIN TUMOURS.....	99

FIGURE 5.1	EFFECT OF TREATMENT ON TUMOUR VOLUME IN MM3 SHOWING NO SIGNIFICANT DIFFERENCE IN TUMOUR VOLUME AMONG THE GROUPS	100
FIGURE 5.2	ALBUMIN AND SUBSTANCE P (SP) IMMUNOREACTIVITY	101
FIGURE 5.3	ANIMAL WEIGHT CHANGE FOLLOWING TUMOUR CELL INOCULATION AND TREATMENT *P<0.05.....	102
FIGURE 6.1	SUBSTANCE P (SP) IMMUNOREACTIVITY WITH METASTATIC BRAIN TUMOUR GROWTH.....	114
FIGURE 6.2	BRAIN WATER CONTENT	115
FIGURE 6.3	EVANS BLUE EXTRAVASATION	117
FIGURE 6.4	ALBUMIN IMMUNOREACTIVITY WITH TUMOUR INOCULATION AND TREATMENT	118
FIGURE 7.1	CELL VIABILITY ASSAY.....	132
FIGURE 7.2	NK1 RECEPTOR IMMUNOREACTIVITY	134
FIGURE 7.3	TUMOUR GROWTH.....	136
FIGURE 7.4	TUMOUR GROWTH CHARACTERISTICS.....	138
FIGURE 7.5	TUMOUR AND PERITUMORAL GLIAL REACTION	140
FIGURE 7.6	BRAIN MICROENVIRONMENT REACTION TO TUMOUR GROWTH	142

Abstract

Secondary brain tumours occur when cancer cells enter the circulation from their primary site and colonise the brain, previously shown to occur across the blood-brain barrier (BBB). Substance P (SP), a neurogenic inflammatory mediator, acting predominantly through NK1 receptors plays a role in opening the BBB and in the formation of oedema following stroke and brain trauma. It is hypothesised that SP may also promote the extravasation of tumour cells through the BBB, formation of peritumoral oedema and progression of secondary brain tumours.

Walker 256 rat breast carcinoma cells obtained from the Centre for Medical Research, Tohoku University had superior tumorigenic properties compared to cells from the American Type Culture Collection, and were therefore subsequently used in two albino Wistar rat models of tumorigenesis.

Firstly, internal carotid artery tumour cell injection was used to establish the effect of tumour cell extravasation across the BBB on brain albumin, endothelial barrier antigen (EBA) and SP immunoreactivity. I then determined if NK1 receptor antagonists could prevent tumour cell extravasation, by evaluating tumour incidence and volume.

Secondly, a stereotaxic direct inoculation model was used to investigate the effect of NK1 receptor antagonists on brain tumour growth and peritumoral oedema, compared with dexamethasone treatment. Evan's blue extravasation and albumin immunoreactivity were used to assess BBB permeability, and brain water content to evaluate cerebral oedema. Tumour volume, Ki67 immunoreactivity, caspase-3 immunoreactivity and tumour cell density were used as measures of tumour growth. Furthermore, cell viability and cell death assays determined if NK1 antagonists or dexamethasone treatment cause alterations in tumour cell growth in vitro.

In the carotid model, SP and albumin immunoreactivity increased in the brain during the extravasation of tumour cells, and in the peritumoral area of established tumours. The invaded blood vessels lacked EBA immunoreactivity, indicating loss of BBB properties. However, NK1 antagonists administered in the first three days following tumour cell injection failed to reduce tumour incidence or volume, suggesting that

extravasation may be a multifactorial process, and that NK1 receptor antagonism alone is not sufficient to prevent tumour extravasation and growth.

In the direct inoculation model, NK1 receptor antagonists did not reduce peritumoral oedema or decrease tumour growth when used to treat established brain metastases. In contrast, dexamethasone, the standard treatment for peritumoral oedema, caused a reduction in brain water content and decreased tumour volume, but not tumour growth. The decrease in tumour volume with dexamethasone reflects reduced fluid content, as there was increased tumour cell density with no change in immunoreactivity to Ki67 (marker for proliferation) or caspase-3 (marker for apoptosis). Furthermore, in vitro studies showed no effect for dexamethasone on tumour cell viability. These results suggest that peritumoral oedema is driven by classical inflammation rather than neurogenic inflammation in the direct inoculation model.

In conclusion, in these models of secondary brain tumours, SP does not appear to play a role sufficient to promote NK1 receptor antagonism as an appropriate preventative treatment for brain metastasis, as an anticancer agent, or as an alternative to dexamethasone for the management of peritumoral oedema.